403 Page

404 Page

You are now leaving www.radiologysolutions.bayer.com

MEDRAD® Centargo CT  Injection System

MEDRAD® Stellant FLEX CT Injection System

CT Contrast Agent

View our full CT Portfolio

Angiography

Molecular Imaging

Breast Imaging

SOLUTIONS

Personalized Dosing Software

MEDRAD® Mark 7 Arterion Injection System

MEDRAD® MRXperion MR Injection System

Discontinued Products

Additional Product Information

MR Contrast Case Library

RESOURCES

Portfolio Solutions

MEDRAD® Intego PET Infusion System

MR Contrast Agents

View our full Angiography Portfolio

ANGIOGRAPHY

Syringes and Disposables 

Cortenic™ Connectivity

Contrast Reimbursement and Purchasing

View our full MR Portfolio

View our full Molecular Imaging Portfolio

Contrast Dose Management

Radimetrics® Radiation Dose Management

Imaging System Interfaces (ISI) 

View our full Software Portfolio

SOFTWARE

MOLECULAR IMAGING

OTHER PRODUCT RESOURCES

Products

Resources

Customer Portal

Bayer Logo

bottom

small_Cardiovascular_32px.png

Anticoagulation

Chronic Kidney Disease

Hearth Failure

small_Womens_health_32px.png

Women's Health

small_Hematology_32px.png

Hematology

small_Ophthalmology_32px.png

Ophthalmology

Cardiovascular

<h3>EOVIST® IMPORTANT SAFETY INFORMATION and INDICATION &nbsp;</h3><section class="border">WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSISRisk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Eovist is not approved for intrathecal use.Nephrogenic Systemic Fibrosis GBCAs increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of Eovist in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.The risk of NSF appears highest among patients with:<ul><li data-list-item-id="e6c4084c63910bdb211cddbaf9c37590b">Chronic, severe kidney disease (GFR &lt;30 mL/min/1.73m2), or</li><li data-list-item-id="eb2e4a9835be6632435ef26d235a01cc2">Acute kidney injury</li></ul>Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age &gt;60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.For patients at highest risk for NSF, do not exceed the recommended Eovist dose and allow a sufficient period of time for elimination of the drug from the body prior to any readministration.</section> Contraindication and Important Information about Hypersensitivity Reactions: Eovist® is contraindicated in patients with history of severe hypersensitivity reactions to Eovist®. Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe, including shock have occurred following Eovist® administration. Before Eovist® administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to Eovist®.Gadolinium Retention: Gadolinium is retained for months or years in several organs. Linear GBCAs cause more retention than macrocyclic GBCAs. At equivalent doses, retention varies among the linear agents. Retention is lowest and similar among the macrocyclic GBCAs. Consequences of gadolinium retention in the brain have not been established, but they have been established in the skin and other organs in patients with impaired renal function. While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions. Consider the retention characteristics of the agent and minimize repetitive GBCA studies, when possible.Acute Kidney Injury: In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis has been observed with the use of GBCAs. Do not exceed the recommended dose; the risk of acute kidney injury may increase with higher than recommended doses.Extravasation and Injection Site Reactions: Extravasation into tissues during Eovist® administration may result in local tissue reactions such as myocyte necrosis and inflammation. Ensure catheter and venous patency before the injection.Interference with Laboratory Tests: Serum iron determination using complexometric methods may result in falsely high or low values for up to 24 hours after the examination with Eovist®.Interference with Visualization of Liver Lesions: End stage renal failure or hepatic failure may impair Eovist® imaging performance. In patients with elevated serum ferritin or serum bilirubin &gt;3 mg/dL, reduced hepatic contrast was observed.Adverse Reactions: The most frequent (≥0.5%) adverse reactions associated with Eovist® are nausea (1.1%), headache (1.1%), feeling hot (0.8%), dizziness (0.6%), and back pain (0.6%).INDICATIONEovist® (gadoxetate disodium) is indicated for use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adult and pediatric patients, including term neonates, with known or suspected focal liver disease.<a href="https://labeling.bayerhealthcare.com/html/products/pi/Eovist_PI.pdf" target="_blank">Please see Full Prescribing Information for Eovist®.</a> <a href="https://labeling.bayerhealthcare.com/html/products/pi/Eovist_Spanish_PI.pdf" target="_blank">Consulte la información de prescripción completa para Eovist.&nbsp;</a> <a href="https://labeling.bayerhealthcare.com/html/products/pi/Eovist_MG.pdf" target="_blank">Medication Guide</a> <a href="https://labeling.bayerhealthcare.com/html/products/pi/Eovist_MG_Spanish.pdf">Guía del Medicamento</a>

Eovist® (gadoxetate disodium) injection 0.25mmol/mL